Rybelsus sales disappoint while Ozempic surpasses expectations at Novo Nordisk

Compared to last year, both Rybelsus and Ozempic generated more revenue in Q2.

Photo: Novo Nordisk / PR

Novo Nordisk’s primary business area, dubbed Diabetes Care, fared worse than expected in the second quarter of 2022. The Ozempic drug once again generated higher-than-expected growth but Rybelsus disappointed compared to analyst estimates, the firm’s accounting report for the period showed Wednesday.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs